| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter B Crin. The mTOR signalling cascade: paving new roads to cure neurological disease. Nature reviews. Neurology. vol 12. issue 7. 2018-08-13. PMID:27340022. |
a particularly exciting feature of the tale of mtor discovery is that pharmacological mtor inhibitors have shown clinical benefits in some neurological disorders, such as tuberous sclerosis complex, and are being considered for clinical trials in epilepsy, autism, dementia, traumatic brain injury, and stroke. |
2018-08-13 |
2023-08-13 |
Not clear |
| Anna Jeong, Michael Won. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development. Journal of child neurology. vol 33. issue 1. 2018-07-30. PMID:29246093. |
mtor inhibitors prevent epilepsy and associated pathogenic mechanisms of epileptogenesis in mouse models of tuberous sclerosis complex and are currently in clinical trials for drug-resistant seizures in these patients. |
2018-07-30 |
2023-08-13 |
mouse |
| Qiuling Wang, Gaofeng Zhao, Zhenzhen Yang, Xia Liu, Ping Xi. Downregulation of microRNA‑124‑3p suppresses the mTOR signaling pathway by targeting DDIT4 in males with major depressive disorder. International journal of molecular medicine. vol 41. issue 1. 2018-07-09. PMID:29115444. |
it was also demonstrated that mir‑124‑3p expression was positively associated with mtor signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex. |
2018-07-09 |
2023-08-13 |
Not clear |
| Alessia Mingarelli, Aglaia Vignoli, Francesca La Briola, Angela Peron, Lucio Giordano, Giuseppe Banderali, Maria Paola Canevin. Dramatic relapse of seizures after everolimus withdrawal. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 22. issue 1. 2018-07-02. PMID:28888335. |
tuberous sclerosis complex (tsc) is an autosomal dominant multisystemic disorder caused by deregulation of the mtor pathway, and represents one of the leading genetic causes of epilepsy. |
2018-07-02 |
2023-08-13 |
Not clear |
| Shai Shrot, Misun Hwang, Carl E Stafstrom, Thierry A G M Huisman, Bruno P Soare. Dysplasia and overgrowth: magnetic resonance imaging of pediatric brain abnormalities secondary to alterations in the mechanistic target of rapamycin pathway. Neuroradiology. vol 60. issue 2. 2018-06-22. PMID:29279945. |
it has recently been demonstrated that alterations affecting the mechanistic target of rapamycin (mtor) signaling pathway result in diverse abnormalities such as dysplastic megalencephaly, hemimegalencephaly, ganglioglioma, dysplastic cerebellar gangliocytoma, focal cortical dysplasia type iib, and brain lesions associated with tuberous sclerosis. |
2018-06-22 |
2023-08-13 |
Not clear |
| Laura C Armstrong, Grant Westlake, John P Snow, Bryan Cawthon, Eric Armour, Aaron B Bowman, Kevin C Es. Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming. Human molecular genetics. vol 26. issue 23. 2018-05-24. PMID:28973543. |
tuberous sclerosis complex (tsc) is a pediatric disorder of dysregulated growth and differentiation caused by loss of function mutations in either the tsc1 or tsc2 genes, which regulate mtor kinase activity. |
2018-05-24 |
2023-08-13 |
human |
| Mo-Han Zhang, Jing-Zhi Jiang, Ying-Lan Cai, Li-Hua Piao, Zheng Ji. Significance of dynamic changes in gastric smooth muscle cell apoptosis, PI3K-AKT-mTOR and AMPK-mTOR signaling in a rat model of diabetic gastroparesis. Molecular medicine reports. vol 16. issue 2. 2018-05-10. PMID:28627597. |
the expression levels of pi3k and phosphorylated (p‑) akt, ampk, mtor, tuberous sclerosis complex 2, p70 ribosomal s6 kinase, and eukaryotic translation initiation factor 4‑binding protein 1 were determined in gastric muscles using western blot analysis. |
2018-05-10 |
2023-08-13 |
rat |
| Jonathan O Lipton, Lara M Boyle, Elizabeth D Yuan, Kevin J Hochstrasser, Fortunate F Chifamba, Ashwin Nathan, Peter T Tsai, Fred Davis, Mustafa Sahi. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy. Cell reports. vol 20. issue 4. 2018-05-07. PMID:28746872. |
tuberous sclerosis complex (tsc) is a neurodevelopmental disorder characterized by mutations in either the tsc1 or tsc2 genes, whose products form a critical inhibitor of the mechanistic target of rapamycin (mtor). |
2018-05-07 |
2023-08-13 |
mouse |
| Haichang Yin, Lili Zhao, Siqi Li, Lijing Xu, Yiping Wang, Hongyan Che. Impaired Cellular Energy Metabolism Contributes to Duck-Enteritis-Virus-Induced Autophagy via the AMPK-TSC2-MTOR Signaling Pathway. Frontiers in cellular and infection microbiology. vol 7. 2018-04-23. PMID:29018776. |
we also found that tuberous sclerosis (tsc) 2 was a key mediator between ampk and mtor through activation by phosphorylation. |
2018-04-23 |
2023-08-13 |
Not clear |
| Premranjan Kumar, Thiagarajan Raman, Mitali Madhusmita Swain, Rangnath Mishra, Arttatrana Pa. Hyperglycemia-Induced Oxidative-Nitrosative Stress Induces Inflammation and Neurodegeneration via Augmented Tuberous Sclerosis Complex-2 (TSC-2) Activation in Neuronal Cells. Molecular neurobiology. vol 54. issue 1. 2018-02-09. PMID:26738854. |
our results show that the increases in phosphorylation of akt and erk1/2mapk are associated with increased accumulations of reactive oxygen species (ros) in neuronal cells, which simultaneously enhanced phosphorylations of tuberous sclerosis complex-2 (tsc-2) and mammalian target of rapamycin (mtor) in the diabetic brain and in hg-exposed neuronal cells. |
2018-02-09 |
2023-08-13 |
Not clear |
| Nicholas T Olney, Carolina Alquezar, Eliana Marisa Ramos, Alissa L Nana, Jamie C Fong, Anna M Karydas, Joanne B Taylor, Melanie L Stephens, Andrea R Argouarch, Victoria A Van Berlo, Deepika R Dokuru, Elliott H Sherr, Gregory A Jicha, William P Dillon, Rahul S Desikan, Mary De May, William W Seeley, Giovanni Coppola, Bruce L Miller, Aimee W Ka. Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia. Acta neuropathologica. vol 134. issue 5. 2018-01-31. PMID:28828560. |
linking tuberous sclerosis complex, excessive mtor signaling, and age-related neurodegeneration: a new association between tsc1 mutation and frontotemporal dementia. |
2018-01-31 |
2023-08-13 |
Not clear |
| Mark R Woodford, Rebecca A Sager, Elijah Marris, Diana M Dunn, Adam R Blanden, Ryan L Murphy, Nicholas Rensing, Oleg Shapiro, Barry Panaretou, Chrisostomos Prodromou, Stewart N Loh, David H Gutmann, Dimitra Bourboulia, Gennady Bratslavsky, Michael Wong, Mehdi Mollapou. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. The EMBO journal. vol 36. issue 24. 2017-12-28. PMID:29127155. |
the tumor suppressors tsc1 and tsc2 form the tuberous sclerosis complex (tsc), a regulator of mtor activity. |
2017-12-28 |
2023-08-13 |
Not clear |
| Tao Jiang, Jiang Du, Raynald, Junmei Wang, Chunde L. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex. World neurosurgery. vol 107. 2017-12-25. PMID:28866062. |
presurgical administration of mtor inhibitors in patients with large subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
2017-12-25 |
2023-08-13 |
Not clear |
| Sergiusz Jóźwiak, Krzysztof Sadowski, Katarzyna Kotulska, Robert A Schwart. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatric neurology. vol 61. 2017-12-15. PMID:27222056. |
topical use of mammalian target of rapamycin (mtor) inhibitors in tuberous sclerosis complex-a comprehensive review of the literature. |
2017-12-15 |
2023-08-13 |
human |
| Sergiusz Jóźwiak, Krzysztof Sadowski, Katarzyna Kotulska, Robert A Schwart. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatric neurology. vol 61. 2017-12-15. PMID:27222056. |
the discovery of the mammalian target of rapamycin (mtor) pathway and its involvement in tuberous sclerosis complex-related pathology has led to the introduction of mtor inhibitors into clinical practice. |
2017-12-15 |
2023-08-13 |
human |
| Sergiusz Jóźwiak, Krzysztof Sadowski, Katarzyna Kotulska, Robert A Schwart. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatric neurology. vol 61. 2017-12-15. PMID:27222056. |
topical administration of mtor inhibitors for skin lesions related to tuberous sclerosis complex may represent a reasonable alternative for more invasive procedures. |
2017-12-15 |
2023-08-13 |
human |
| Sergiusz Jóźwiak, Krzysztof Sadowski, Katarzyna Kotulska, Robert A Schwart. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatric neurology. vol 61. 2017-12-15. PMID:27222056. |
the aim of this review was to systematically analyze available literature on the use of topical mtor inhibitors to treat dermatologic lesions related to tuberous sclerosis complex. |
2017-12-15 |
2023-08-13 |
human |
| David N Franz, Jamie K Capa. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet journal of rare diseases. vol 12. issue 1. 2017-12-01. PMID:28288694. |
mtor inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. |
2017-12-01 |
2023-08-13 |
Not clear |
| Darius Ebrahimi-Fakhari, Afshin Saffari, Lara Wahlster, Mustafa Sahi. Using tuberous sclerosis complex to understand the impact of MTORC1 signaling on mitochondrial dynamics and mitophagy in neurons. Autophagy. vol 13. issue 4. 2017-11-20. PMID:28121223. |
constitutive activation of the mtor pathway is a key feature of defects in the tuberous sclerosis complex and other genetic neurodevelopmental diseases, collectively referred to as mtoropathies. |
2017-11-20 |
2023-08-13 |
Not clear |
| Sara Baldassari, Laura Licchetta, Paolo Tinuper, Francesca Bisulli, Tommaso Pippucc. GATOR1 complex: the common genetic actor in focal epilepsies. Journal of medical genetics. vol 53. issue 8. 2017-10-30. PMID:27208208. |
the gator1/mtor signalling represents a promising therapeutic target in fes due to mutations in mtor pathway genes, as in tuberous sclerosis complex, another mcd-associated epilepsy caused by mtor signalling hyperactivation. |
2017-10-30 |
2023-08-13 |
Not clear |